A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.

As a result, the OS benefit showed a favorable trend for the afatinib group compared with the osimertinib group, as shown in Figure 3 , and Supplementary Figure S4 , available at https://doi.org/10.1016/j.esmoop.2021.100115 .

also in 1,335 other papers

Consequently, the subgroup analysis with the propensity score method revealed that afatinib had a strong trend of prolonged TD-TKI and OS over osimertinib in patients with the L858R mutation and without brain metastasis.

also in 5,725 other papers